Comparison of ELISA and HPLC-MS methods for the determination of exenatide in biological and biotechnology-based formulation matrices

The development of biotechnology-based active pharmaceutical ingredients, such as GLP-1 analogs, brought changes in type 2 diabetes treatment options. For better therapeutic efficiency, these active pharmaceutical ingredients require appropriate administration, without the development of adverse eff...

Full description

Bibliographic Details
Main Author: Pinho, A (author)
Other Authors: Fortuna, A (author), Falcão, A (author), Santos, AC (author), Seiça, R (author), Estevens, C (author), Veiga, F (author), Ribeiro, A (author)
Format: article
Language:eng
Published: 2019
Subjects:
ELISA
Exenatide
HPLC
Therapeutic drug monitoring
Type 2 diabetes
Online Access:https://hdl.handle.net/10216/136312
Country:Portugal
Oai:oai:repositorio-aberto.up.pt:10216/136312

Internet

https://hdl.handle.net/10216/136312

Similar Items